Agios Pharmaceuticals (NASDAQ:AGIO) Stock Gets Price Target Bump from HC Wainwright

Agios Pharmaceuticals (NASDAQ:AGIO) had its price target raised by stock analysts at HC Wainwright from $55.00 to $62.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright‘s price target indicates a potential upside of 119.31% from the company’s current price.

Several other research analysts have also recently weighed in on AGIO. TD Cowen raised Agios Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 24th. Truist Financial dropped their price target on shares of Agios Pharmaceuticals from $39.00 to $37.00 and set a “buy” rating on the stock in a research report on Wednesday, October 7th. Bank of America upped their price target on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the company a “buy” rating in a report on Monday, September 21st. Citigroup lifted their price objective on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday, September 21st. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Agios Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $42.38.

Agios Pharmaceuticals Price Performance

AGIO opened at $28.27 on Friday. The business has a 50 day moving average price of $33.37 and a two-hundred day moving average price of $31.75. The company has a market capitalization of $1.69 billion, a price-to-earnings ratio of -4.03 and a beta of 0.66. Agios Pharmaceuticals has a 1-year low of $22.24 and a 1-year high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.24) by $0.15. Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. The company had revenue of $55.39 million for the quarter, compared to analysts’ expectations of $51.65 million. Equities analysts expect that Agios Pharmaceuticals will post -5.85 EPS for the current fiscal year.

Insider Activity

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 7,866 shares of the business’s stock in a transaction on Monday, October 26th. The shares were sold at an average price of $37.69, for a total transaction of $296,469.54. Following the sale, the insider directly owned 54,645 shares of the company’s stock, valued at $2,059,570.05. The trade was a 12.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 9,855 shares of company stock worth $371,112 in the last quarter. 5.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of institutional investors have recently bought and sold shares of AGIO. BlackRock Inc. acquired a new stake in Agios Pharmaceuticals during the second quarter valued at $239,582,000. Assenagon Asset Management S.A. increased its position in Agios Pharmaceuticals by 1,714.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,886,412 shares of the biopharmaceutical company’s stock worth $62,723,000 after purchasing an additional 1,782,457 shares during the last quarter. ADAR1 Capital Management LLC acquired a new position in Agios Pharmaceuticals in the 2nd quarter worth about $47,800,000. Dimensional Fund Advisors LP increased its position in Agios Pharmaceuticals by 14.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,151,614 shares of the biopharmaceutical company’s stock worth $38,940,000 after purchasing an additional 147,273 shares during the last quarter. Finally, Parkman Healthcare Partners LLC purchased a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth about $24,828,000.

Key Headlines Impacting Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Agios reported a Q3 loss of $1.09 per share, narrower than the cited consensus estimate of $1.24, and revenue of $55.39 million, above estimates of $51.65 million. The per-share loss also improved from $1.78 a year earlier. Earnings results
• Positive Sentiment: Mitapivat revenue rose more than fourfold, highlighting growing commercial traction. Agios expects an FDA decision on mitapivat for sickle cell disease in February 2027, a potentially important future catalyst. Mitapivat sales and FDA timing
• Positive Sentiment: Agios plans to present new clinical data on mitapivat in sickle cell disease and AG-236 in polycythemia vera at the ASH 2026 meeting, offering investors additional updates on its rare-hematology pipeline. ASH 2026 data announcement
• Neutral Sentiment: The company aims to eliminate more than 100 R&D positions. The cuts could reduce costs, but investors may also consider whether a smaller research workforce affects development and execution. R&D workforce cuts
• Negative Sentiment: Despite the earnings beat, Agios remains loss-making, leaving its outlook dependent on continued product growth and successful clinical and regulatory milestones. Quarterly results and business update

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.